BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-598@pharmaconomics
DTSTAMP:20260707T034505Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:ACAD Phase 2 — trofinetide
DESCRIPTION:Phase 2 trial results for trofinetide in Rett syndrome are due Nov 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1070494/000119312526209253/acad-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/598
URL:https://www.pharmaconomics.com/e/598
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ACAD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR